Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer by Jonathan Henricks, Tyler Haddad, Omair Ahmed, Jonathan Schoenhals, Pavnesh Kumar, Ryan Wilson, Jianing Ma, Jing Gennie Wang, Michael Wert, Vincent Esguerra, Ian Bentley, Kai Johnson, Daniel Stover, Sachin R. Jhawar, Margaret Gatti-Mays, Kevin Ho

Subjects: “…Trastuzumab-Deruxtecan…”
Get full text

Modeling the impact of using trastuzumab deruxtecan in patients with breast cancer on reducing cancer mortality in Russia by N. A. Avxentyev, Yu. V. Makarova, A. S. Makarov

Subjects: Get full text

Pneumonitis as a side effect of breast cancer treatment: T-DXd and/or SBRT? by Džana Bjelić, Sara Bognar, Jelena Benčić, Manuela Bajan, Natalija Dedić Plavetić

Subjects: Get full text

Safety and efficacy of combined trastuzumab-deruxtecan and concurrent radiation therapy in breast cancer. The TENDANCE multicentric French study by K. Debbi, M.A. Benderra, J. Medioni, C. Durdux, N.H. To, C. Boukhobza, N. Grellier, A. Benmaziane, L. Monnier, J. Gligorov, E. Assaf, Y. Belkacemi

Subjects: “…Trastuzumab deruxtecan…”
Get full text

Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan by Nelson S Moss, Umberto Tosi, Bianca D Santomasso, Kathryn Beal, Shanu Modi

Subjects: Get full text

Clinically significant radiation necrosis following trastuzumab-deruxtecan and brain stereotactic radiosurgery: A case series in breast cancer patients by Victoria Wytiaz, Anne Schott, Aki Morikawa, Michelle M. Kim

Subjects: Get full text

Long-Term Complete Response to Trastuzumab Deruxtecan in a Case of Unresectable Gastric Cancer by Hiroaki Yamane, Yoichi Sugiyama, Toshiaki Komo, Kosuke Shibata, Tatsuya Tazaki, Mohei Koyama, Masaru Sasaki

Subjects: “…trastuzumab deruxtecan…”
Get full text

A Dramatic Clinical Response to Trastuzumab-Deruxtecan in a Patient with HER-2 Low Breast Cancer with Untreated Leptomeningeal Metastasis and Hydrocephalus by Sarah Hussain, Robert Nordal, Danny Ng, Morgan Willson, Xiaolan Feng

Subjects: Get full text

Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice by Giulia Notini, Giulia Notini, Matteo Maria Naldini, Matteo Maria Naldini, Lorenzo Sica, Lorenzo Sica, Giulia Viale, Giulia Viale, Alessia Rognone, Alessia Rognone, Stefania Zambelli, Stefania Zambelli, Patrizia Zucchinelli, Patrizia Zucchinelli, Marta Piras, Marta Piras, Carlo Bosi, Carlo Bosi, Marco Mariani, Marco Mariani, Daniela Aldrighetti, Daniela Aldrighetti, Giampaolo Bianchini, Giampaolo Bianchini, Luca Licata, Luca Licata

Subjects: Get full text

Efficacy and safety of trastuzumab deruxtecan therapy by Nina Privšek, Simona Borštnar, Cvetka Grašič Kuhar

Subjects: Get full text

Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective by Jan-Willem Henning, Christine Brezden-Masley, Karen Gelmon, Stephen Chia, Shane Shapera, Micheal McInnis, Daniel Rayson, Jamil Asselah

Subjects: “…trastuzumab deruxtecan…”
Get full text

Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a cas... by Axel de Bernardi, Thomas Bachelot, Thomas Bachelot, Louis Larrouquère, Louis Larrouquère

Subjects: Get full text

How I treat HER2-low advanced breast cancer by Ilana Schlam, Sara M. Tolaney, Paolo Tarantino

Subjects: Get full text

Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy by Markus Falk, Eva Willing, Stefanie Schmidt, Stefanie Schatz, Marco Galster, Markus Tiemann, Joachim H. Ficker, Wolfgang M. Brueckl

Subjects: Get full text

Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan by Stefano Testa, James C. Dickerson, Melinda Telli

Subjects: Get full text

Dramatic Recovery of Vision after Trastuzumab Deruxtecan Treatment of HER2-Positive Breast Cancer with Pituitary Metastasis by Chiaki Matsui, Nobuhiro Shibata, Chie Hirai, Manami Tada, Yuichiro Kikawa, Tomoharu Sugie

Subjects: Get full text

Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report by Chen Y, Liu C, Wen X, Wang C, He J

Subjects: Get full text

Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04 by Mei Zhan, Mei Zhan, Zijia Huang, Zijia Huang, Ting Xu, Ting Xu, Xinyi Xu, Hanrui Zheng, Hanrui Zheng, Fengbo Wu, Fengbo Wu

Subjects: Get full text

Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study) by Gavin P. Dowling, Sinead Toomey, Philip Bredin, Imelda Parker, Eibhlin Mulroe, Jacinta Marron, Olivia McLoughlin, Ausra Teiserskiene, Colm Power, Anne Marie O’Shea, Megan Greally, Patrick G. Morris, Deirdre Duke, Arnold D. K. Hill, Bryan T. Hennessy

Subjects: Get full text

Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review by Linehan AS, Fitzpatrick OM, Morris PG

Subjects: Get full text